HER2 -vaccine til lokalt avanceret brystkræft
Fase I-forsøg på en kimær (trastuzumab-lignende og pertuzumab-lignende) HER2 B-cellepeptidvaccine emulgeret i ISA 720 Adjuvans til lokalt avanceret HER2-positiv brystkræft
The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Niraj Shah
- Telefonnummer: 317-278-3420
- E-mail: shahnir@iu.edu
Studiesteder
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Rekruttering
- Indiana University Melvin & Bren Simon Comprehensive Cancer Center
-
Ledende efterforsker:
- Pravin Kaumaya, PhD
-
Kontakt:
- Niraj Shah
- Telefonnummer: 317-278-3420
- E-mail: shahnir@iu.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
≥ 18 years old at the time of informed consent
-
Ability to provide written informed consent and HIPAA authorization CTO-IUSCC-0864
-
Histologically confirmed HER2 positive breast cancer
- Any Estrogen Receptor/Progesterone Receptor status is allowed.
- HER2 positive is defined as HER2 3+ by immunohistochemistry (IHC) or 2+ by IHC associated with a fluorescence in situ hybridization (FISH) ratio of > 2.0 or > 6 total HER2 gene copies per cell.
-
High-risk disease defined as one of the following:
- Any residual invasive carcinoma in the breast or axillary nodes in the final pathology from resected tumor following neoadjuvant taxane and trastuzumab-based chemotherapy
- Inflammatory phenotype at the time of diagnosis per the treating physician
- Clinical stage III disease at the time of diagnosis per the treating physician and/or clinical imaging
- Locally recurrent disease and have undergone definitive local therapy
-
Received at least six months of HER2 targeted therapy with trastuzmab +/- pertuzumab TDM-1, or others in the neoadjuvant or adjuvant setting
a. Any combination of HER2 targeted therapy in the curative setting is allowed, including neratinib or others on a clinical trial
-
Completed last dose of HER2 targeted therapy no more than 6 months prior to registration
-
Completed last dose of cytotoxic chemotherapy or radiation at least 30 days prior to registration with resolution of any prior toxicity to ≤ 2 with the exception of alopecia
-
ECOG performance status of 0 to 2
-
Adequate organ function as indicated by:
- Total bilirubin < 1.5 mg/dL (except in patients with documented Gilbert's disease, who must have a total bilirubin < 3.0 mg/dL)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.0 x ULN
- Calculated creatinine clearance of > 60 mL/min using the Cockcroft-Gault formula
- Absolute neutrophil count (ANC) > 1.0 K/mm3
- Platelets > 100 K/ mm3
-
Adequate cardiac function defined as left ventricular ejection fraction (LVEF) above the institutional lower limit of normal by echocardiogram or MUGA obtained within 90 days of registration
-
Women of childbearing potential must have a negative serum pregnancy test within 14 days of protocol registration. Women are considered to have childbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) unless they meet one of the following criteria:
- Has undergone a hysterectomy or bilateral oophorectomy; or
- Has been naturally amenorrheic for at least 12 consecutive months.
-
Women of childbearing potential and men must agree to use one effective contraception throughout the study and for 6 months after the last study treatment.
Note: Acceptable methods of birth control include abstinence, partner with previous vasectomy, placement of an intrauterine device (IUD), condom with spermicidal foam/gel/film/cream/suppository, diaphragm or cervical vault cap, or hormonal birth control (pills or injections).
Exclusion Criteria:
-
Any distant disease recurrence.
-
Patients with active malignancy other than breast cancer. Note: Patients with prior malignancies without recurrence after standard treatment will not be excluded.
-
Patients receiving or planned to receive adjuvant CDK4/6 inhibitor therapy
-
Patients who are {MVF-HER-2(266-296) and MVF-HER-2 (597-626)} immediate hypersensitivity skin test positive.
-
Patients who require or likely to require corticosteroids or other immunosuppressives
-
Patients with active autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis dermato-myositis, or a vasculitic syndrome.
Note: At the discretion of the treating physician, patients who show disease control for at least 6 months and do not require immunosuppressives may be enrolled.
-
Patients who have developed anaphylactic responses to other vaccines.
-
Patients who have evidence of active infection that requires antibiotic therapy. Patients must have been off antibiotic treatment for at least 3 weeks prior to initiating treatment and must be confirmed to be clear of the infection.
-
Known seropositive or active viral infection with human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV). Seropositivity due to vaccination are eligible.
-
Uncontrolled illness that would limit safety or compliance with study procedures including, but not limited to, active infection, congestive heart failure, unstable angina, or cardiac arrhythmia.
-
Patients with serious uncontrolled cardiopulmonary disorders, including congestive heart failure, symptomatic coronary artery disease, serious cardiac arrhythmia, and symptomatic chronic obstructive pulmonary disease or patients with other serious uncontrolled medical diseases. At the discretion of the treating physician, patients who show disease control for at least 6 months may be enrolled.
-
History of splenectomy
-
Pregnant or breast feeding.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: HER2 Vaccine Arm
MVF-HER2 266-296 and MVF HER2 597-626 peptide vaccines are combined in 1.5 mg doses of each peptide into a 3.0 mg total dose. This is administered intramuscularly in the gluteus maximus once every 21 days for three doses, in alternating sides (i.e. left->right->left), with a booster administered at 6 months. |
MVF-HER2 266-296 and MVF HER2 597-626 peptide vaccines |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Evaluation of safety and toxicity at regular intervals by NCI common toxicity criteria 5.0
Tidsramme: through completion of 3 vaccine series (i.e. up to day 64 post final vaccine injection)
|
Number of adverse events as assessed by the NCI CTCAE v. 5.0 |
through completion of 3 vaccine series (i.e. up to day 64 post final vaccine injection)
|
|
Immune Response
Tidsramme: through completion of 3 vaccine series (i.e. up to day 64 post final vaccine injection)
|
Humoral immune response will be measured by ELISA quantification of IgM and IgG antibodies to HER2 (597-626) and HER2 (266-296). |
through completion of 3 vaccine series (i.e. up to day 64 post final vaccine injection)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Pravin Kaumaya, PhD, Indiana University
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CTO-IUSCCC-0864
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .